AR122180A1 - Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl - Google Patents

Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl

Info

Publication number
AR122180A1
AR122180A1 ARP210101427A ARP210101427A AR122180A1 AR 122180 A1 AR122180 A1 AR 122180A1 AR P210101427 A ARP210101427 A AR P210101427A AR P210101427 A ARP210101427 A AR P210101427A AR 122180 A1 AR122180 A1 AR 122180A1
Authority
AR
Argentina
Prior art keywords
methods
ldl cholesterol
related disorders
pcsk9 inhibitors
treat
Prior art date
Application number
ARP210101427A
Other languages
English (en)
Spanish (es)
Inventor
Andrew W Hamer
Ian Matthew Bridges
Huei Wang
Andrea Ruzza
Christopher Kurtz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR122180A1 publication Critical patent/AR122180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ARP210101427A 2020-05-29 2021-05-27 Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl AR122180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29

Publications (1)

Publication Number Publication Date
AR122180A1 true AR122180A1 (es) 2022-08-24

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101427A AR122180A1 (es) 2020-05-29 2021-05-27 Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl

Country Status (11)

Country Link
US (1) US20230235085A1 (https=)
EP (1) EP4157887A4 (https=)
JP (1) JP2023527542A (https=)
CN (1) CN115916838A (https=)
AR (1) AR122180A1 (https=)
AU (1) AU2021281256A1 (https=)
CA (1) CA3179316A1 (https=)
IL (1) IL298375A (https=)
JO (1) JOP20220322A1 (https=)
TW (1) TW202210524A (https=)
WO (1) WO2021243002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121693519A (zh) 2023-08-14 2026-03-17 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)

Also Published As

Publication number Publication date
WO2021243002A1 (en) 2021-12-02
IL298375A (en) 2023-01-01
TW202210524A (zh) 2022-03-16
JP2023527542A (ja) 2023-06-29
CA3179316A1 (en) 2021-12-02
AU2021281256A1 (en) 2022-12-22
EP4157887A1 (en) 2023-04-05
US20230235085A1 (en) 2023-07-27
CN115916838A (zh) 2023-04-04
JOP20220322A1 (ar) 2022-11-27
EP4157887A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
AR122180A1 (es) Métodos de uso de inhibidores de pcsk9 para tratar trastornos relacionados con el colesterol ldl
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
MX2010004454A (es) Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
MX373298B (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112018076242A2 (pt) inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
NO20082907L (no) Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
MX2019013634A (es) Composiciones y metodos para tratar cancer con mutaciones de braf atipicas.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
MX2015005536A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CU20120034A7 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
SV2009002863A (es) Compuestos anti-hipercolesterolemicos
BR112013002541A2 (pt) uso de ligante sigma, combinação de pelo menos um ligante sigma e de pelo menos um composto opióide ou opiato para administração simultânea, separada ou sequencial e método de tratamento de um paciente que sofre de oih associada à terapia opióide
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
PE20211065A1 (es) Metodo para tratar la epilepsia
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis
BRPI0416812A (pt) métodos e reagentes para o tratamento de desordens inflamatórias
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
CY1120666T1 (el) Μεθοδος για τη θεραπεια ελλειμματων οστικου κενου
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios